FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802561932> ?p ?o ?g. }

• W2802561932 endingPage "1155" @default.
• W2802561932 startingPage "1146" @default.
• W2802561932 abstract "IntroductionNivolumab is the first checkpoint inhibitor approved for the treatment of nonsquamous NSCLC. We report results from the nivolumab Italian expanded access program focusing on never-smokers and patients with EGFR-mutant nonsqamous NSCLC.MethodsNivolumab (3 mg/kg intravenously every 2 weeks) was administered upon physicians’ request to patients who had relapsed after one or more prior systemic treatments for stage IIIB/IV nonsquamous NSCLC. Efficacy and safety were evaluated in patients who received at least one dose of nivolumab.ResultsOf 1588 patients with nonsquamous NSCLC, 305 (19.2%) were never-smokers. EGFR status was available for 1395 patients. Of the 102 patients (6.4%) with EGFR mutation–positive tumors, 51 (50%) were never-smokers. The objective response rate was significantly higher in patients with wild-type EGFR than patients with EGFR-mutant tumors (19.6% versus 8.8% [p = 0.007]), in former and current smokers than in never-smokers (21.5% versus 9.2% [p = 0.0001]), and in never-smokers with wild-type EGFR than in never-smokers with mutant EGFR (11.0% versus 1.9% [p = 0.04]). There was no significant difference in objective response rate between smokers with wild-type EGFR and smokers with mutant EGFR (22.0% versus 20.6%). There was no statistically significant difference in median progression-free survival or in median overall survival. The median overall survival times were 11 months in patients with EGFR wild-type tumors versus 8.3 months in patients with EGFR-mutant tumors, 11.6 months in smokers versus 10.0 months in never-smokers, 11.0 months in never-smokers with EGFR wild-type tumors versus 5.6 months in never-smokers with EGFR-mutant tumors, and 14.1 months in smokers with EGFR-mutant tumors versus 11.3 months in smokers with EGFR wild-type tumors.ConclusionsThe data on the Italian expanded access program in populations with nonsquamous NSCLC suggest that subgroups of patients could benefit differently from nivolumab according to their EGFR mutational status and smoking habits. These results warrant further investigation." @default.
• W2802561932 created "2018-05-17" @default.
• W2802561932 creator A5003664573 @default.
• W2802561932 creator A5017447682 @default.
• W2802561932 creator A5021158045 @default.
• W2802561932 creator A5021264126 @default.
• W2802561932 creator A5023227998 @default.
• W2802561932 creator A5025890835 @default.
• W2802561932 creator A5028269615 @default.
• W2802561932 creator A5032477448 @default.
• W2802561932 creator A5038198711 @default.
• W2802561932 creator A5042028913 @default.
• W2802561932 creator A5042372248 @default.
• W2802561932 creator A5047170696 @default.
• W2802561932 creator A5051919018 @default.
• W2802561932 creator A5052556729 @default.
• W2802561932 creator A5067207689 @default.
• W2802561932 creator A5074033106 @default.
• W2802561932 creator A5075911054 @default.
• W2802561932 creator A5082066847 @default.
• W2802561932 creator A5085306324 @default.
• W2802561932 creator A5085432815 @default.
• W2802561932 creator A5086743021 @default.
• W2802561932 creator A5089283304 @default.
• W2802561932 creator A5091509029 @default.
• W2802561932 date "2018-08-01" @default.
• W2802561932 modified "2023-10-04" @default.
• W2802561932 title "Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients" @default.
• W2802561932 cites W2024492396 @default.
• W2802561932 cites W2049553585 @default.
• W2802561932 cites W2096734361 @default.
• W2802561932 cites W2104347254 @default.
• W2802561932 cites W2112339468 @default.
• W2802561932 cites W2123918574 @default.
• W2802561932 cites W2140980839 @default.
• W2802561932 cites W2156353875 @default.
• W2802561932 cites W2170030318 @default.
• W2802561932 cites W2198093519 @default.
• W2802561932 cites W2293531514 @default.
• W2802561932 cites W2323356988 @default.
• W2802561932 cites W2464620827 @default.
• W2802561932 cites W2468576628 @default.
• W2802561932 cites W2538232731 @default.
• W2802561932 cites W2560704457 @default.
• W2802561932 cites W2567564314 @default.
• W2802561932 cites W2606022415 @default.
• W2802561932 cites W2612760980 @default.
• W2802561932 cites W2625684877 @default.
• W2802561932 cites W2635951006 @default.
• W2802561932 cites W2797675588 @default.
• W2802561932 doi "https://doi.org/10.1016/j.jtho.2018.04.025" @default.
• W2802561932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29730379" @default.
• W2802561932 hasPublicationYear "2018" @default.
• W2802561932 type Work @default.
• W2802561932 sameAs 2802561932 @default.
• W2802561932 citedByCount "65" @default.
• W2802561932 countsByYear W28025619322018 @default.
• W2802561932 countsByYear W28025619322019 @default.
• W2802561932 countsByYear W28025619322020 @default.
• W2802561932 countsByYear W28025619322021 @default.
• W2802561932 countsByYear W28025619322022 @default.
• W2802561932 countsByYear W28025619322023 @default.
• W2802561932 crossrefType "journal-article" @default.
• W2802561932 hasAuthorship W2802561932A5003664573 @default.
• W2802561932 hasAuthorship W2802561932A5017447682 @default.
• W2802561932 hasAuthorship W2802561932A5021158045 @default.
• W2802561932 hasAuthorship W2802561932A5021264126 @default.
• W2802561932 hasAuthorship W2802561932A5023227998 @default.
• W2802561932 hasAuthorship W2802561932A5025890835 @default.
• W2802561932 hasAuthorship W2802561932A5028269615 @default.
• W2802561932 hasAuthorship W2802561932A5032477448 @default.
• W2802561932 hasAuthorship W2802561932A5038198711 @default.
• W2802561932 hasAuthorship W2802561932A5042028913 @default.
• W2802561932 hasAuthorship W2802561932A5042372248 @default.
• W2802561932 hasAuthorship W2802561932A5047170696 @default.
• W2802561932 hasAuthorship W2802561932A5051919018 @default.
• W2802561932 hasAuthorship W2802561932A5052556729 @default.
• W2802561932 hasAuthorship W2802561932A5067207689 @default.
• W2802561932 hasAuthorship W2802561932A5074033106 @default.
• W2802561932 hasAuthorship W2802561932A5075911054 @default.
• W2802561932 hasAuthorship W2802561932A5082066847 @default.
• W2802561932 hasAuthorship W2802561932A5085306324 @default.
• W2802561932 hasAuthorship W2802561932A5085432815 @default.
• W2802561932 hasAuthorship W2802561932A5086743021 @default.
• W2802561932 hasAuthorship W2802561932A5089283304 @default.
• W2802561932 hasAuthorship W2802561932A5091509029 @default.
• W2802561932 hasBestOaLocation W28025619321 @default.
• W2802561932 hasConcept C104317684 @default.
• W2802561932 hasConcept C121608353 @default.
• W2802561932 hasConcept C126322002 @default.
• W2802561932 hasConcept C143065580 @default.
• W2802561932 hasConcept C143998085 @default.
• W2802561932 hasConcept C185592680 @default.
• W2802561932 hasConcept C2776256026 @default.
• W2802561932 hasConcept C2777701055 @default.
• W2802561932 hasConcept C2780030458 @default.
• W2802561932 hasConcept C2780739268 @default.
• W2802561932 hasConcept C3019894029 @default.

• next